

16 August 2023

## Treatment of Hereditary Angioedema (HAE)

I would like to submit an FOI request to the Royal Hospitals, Belfast, Northern Ireland, for two main data I couldn't find published:

1. The number of patients diagnosed with Hereditary Angioedema (HAE) types 1, 2, normal C1 and Acquired HAE, and

Number of patients with following:

HAE Type 1: 32  
HAE Type 2: 5  
AAE: <5

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. The volume of medication dispensed and/or consumed from January 1st, 2023, to June 30th, 2023, for each of the products below. If it is more convenient to specify the number of vials, pre-filled syringes, or tablets, that would also be very helpful.

The volume of medication dispensed from January 1st, 2023, to June 30th, 2023, for each of the products below is:

<b>Medications:</b>	<b>Number of vials, pre-filled syringes, or tablets</b>
Berotralstat (Orladeyo)	112 tablets
pdC1-inhibitor (Cinryze and Berinert)	511 Vials
rC1-inhibitor (Ruconest)	6 vials
Icatibant (Firazyr and generic)	68 syringes
Lanadelumab (Takzhyro)	38 syringes